Literature DB >> 33434061

Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas.

Helen E Heslop1, Sandhya Sharma1, Cliona M Rooney1.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33434061      PMCID： PMC8462582          DOI： 10.1200/JCO.20.01709

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  66 in total

1.  Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.

Authors:  Mamta Kalra; Ulrike Gerdemann; Jessica D Luu; Minthran C Ngo; Ann M Leen; Chrystal U Louis; Cliona M Rooney; Stephen Gottschalk
Journal:  Cytotherapy       Date:  2018-11-02       Impact factor: 5.414

2.  Long-term follow up after third-party viral-specific cytotoxic lymphocytes for immunosuppression- and Epstein-Barr virus-associated lymphoproliferative disease.

Authors:  Sajida Kazi; Abhinav Mathur; Gwen Wilkie; Kirsty Cheal; Richard Battle; Neil McGowan; Neil Fraser; Emily Hargreaves; David Turner; John D M Campbell; Marc Turner; Mark A Vickers
Journal:  Haematologica       Date:  2019-02-21       Impact factor: 9.941

3.  Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells.

Authors:  Barbara Withers; Emily Blyth; Leighton E Clancy; Agnes Yong; Chris Fraser; Jane Burgess; Renee Simms; Rebecca Brown; David Kliman; Ming-Celine Dubosq; David Bishop; Gaurav Sutrave; Chun Kei Kris Ma; Peter J Shaw; Kenneth P Micklethwaite; David J Gottlieb
Journal:  Blood Adv       Date:  2017-11-02

4.  Donor T cells to treat EBV-associated lymphoma.

Authors:  H E Heslop; M K Brenner; C M Rooney
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

5.  Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.

Authors:  Ann M Leen; Catherine M Bollard; Adam M Mendizabal; Elizabeth J Shpall; Paul Szabolcs; Joseph H Antin; Neena Kapoor; Sung-Yun Pai; Scott D Rowley; Partow Kebriaei; Bimalangshu R Dey; Bambi J Grilley; Adrian P Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  Blood       Date:  2013-04-22       Impact factor: 22.113

6.  Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation.

Authors:  P Comoli; S Basso; M Zecca; D Pagliara; F Baldanti; M E Bernardo; W Barberi; A Moretta; M Labirio; M Paulli; M Furione; R Maccario; F Locatelli
Journal:  Am J Transplant       Date:  2007-06       Impact factor: 8.086

7.  Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.

Authors:  C M Rooney; C A Smith; C Y Ng; S Loftin; C Li; R A Krance; M K Brenner; H E Heslop
Journal:  Lancet       Date:  1995-01-07       Impact factor: 79.321

8.  Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia.

Authors:  C Rossig; M Pule; B Altvater; S Saiagh; G Wright; S Ghorashian; L Clifton-Hadley; K Champion; Z Sattar; B Popova; A Hackshaw; P Smith; T Roberts; E Biagi; B Dreno; R Rousseau; S Kailayangiri; M Ahlmann; R Hough; B Kremens; M G Sauer; P Veys; N Goulden; M Cummins; P J Amrolia
Journal:  Leukemia       Date:  2017-01-27       Impact factor: 11.528

9.  Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.

Authors:  Ifigeneia Tzannou; Anastasia Papadopoulou; Swati Naik; Kathryn Leung; Caridad A Martinez; Carlos A Ramos; George Carrum; Ghadir Sasa; Premal Lulla; Ayumi Watanabe; Manik Kuvalekar; Adrian P Gee; Meng-Fen Wu; Hao Liu; Bambi J Grilley; Robert A Krance; Stephen Gottschalk; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop; Ann M Leen; Bilal Omer
Journal:  J Clin Oncol       Date:  2017-08-07       Impact factor: 44.544

10.  Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.

Authors:  Mark A Vickers; Gwen M Wilkie; Nicolas Robinson; Nadja Rivera; Tanzina Haque; Dorothy H Crawford; Jacqueline Barry; Neil Fraser; David M Turner; Victoria Robertson; Phil Dyer; Peter Flanagan; Helen R Newlands; John Campbell; Marc L Turner
Journal:  Br J Haematol       Date:  2014-07-26       Impact factor: 6.998
View more
  3 in total

Review 1.  Immunotherapy for KSHV-associated diseases.

Authors:  Kathryn Lurain; Robert Yarchoan; Ramya Ramaswami
Journal:  Curr Opin Virol       Date:  2022-07-05       Impact factor: 7.121

2.  Impact of Tumour Epstein-Barr Virus Status on Clinical Outcome in Patients with Classical Hodgkin Lymphoma (cHL): A Review of the Literature and Analysis of a Clinical Trial Cohort of Children with cHL.

Authors:  Mahdi Nohtani; Katerina Vrzalikova; Maha Ibrahim; Judith E Powell; Éanna Fennell; Susan Morgan; Richard Grundy; Keith McCarthy; Sarah Dewberry; Jan Bouchal; Katerina Bouchalova; Pamela Kearns; Paul G Murray
Journal:  Cancers (Basel)       Date:  2022-09-01       Impact factor: 6.575

Review 3.  Could Changing the DNA Methylation Landscape Promote the Destruction of Epstein-Barr Virus-Associated Cancers?

Authors:  Alison J Sinclair
Journal:  Front Cell Infect Microbiol       Date:  2021-05-28       Impact factor: 5.293
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.